Why predictive intelligence is changing the Medical Science Liaison model

Tern plc

Medical Science Liaisons have traditionally been the scientific connection between pharmaceutical companies and healthcare professionals. Their role is centred on non promotional dialogue, explaining clinical evidence, answering scientific questions and collecting feedback from the field. For many years this model relied on structured engagement plans, established opinion leaders and scheduled interactions at congresses or advisory boards.

However, the information environment surrounding modern healthcare has changed significantly. Scientific debate now develops continuously across digital platforms, academic publications and professional networks. Clinicians discuss emerging evidence faster and across more channels than before.

The challenge for Medical Affairs teams is not simply operational. Pharmaceutical companies increasingly rely on Medical Affairs to provide early visibility on shifts in clinical thinking, treatment behaviour and emerging scientific questions. If insight from the field arrives too slowly, the organisation may miss early signals that influence how therapies are positioned, studied or adopted in practice.

Traditional MSL planning typically focuses on a fixed group of recognised experts. While these relationships remain valuable, influence in healthcare conversations is now more fluid. New voices often emerge quickly around specific research topics, clinical questions or therapeutic developments. Identifying these individuals early can be important for companies seeking to understand how medical narratives are evolving.

Predictive intelligence offers a way to address this gap. By analysing large volumes of healthcare discussion, scientific publication activity and other behavioural signals, data models can identify patterns that indicate where medical conversations are forming and who is shaping them. This allows Medical Affairs teams to prioritise engagement based on current influence rather than relying solely on historical relationships.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines uses AI to turn medical congress discussions into pharma insights

Talking Medicines uses AI to analyse healthcare professional conversations at medical congresses, turning discussions into structured insights that help...

Novo Nordisk deal puts focus on next generation of oral GLP-1 treatments

Novo Nordisk secures rights to Hengrui's investigational HRS-1596 in a potential $2.6bn deal, targeting the development of once-weekly oral...

Device Authority warns supermarket freezer cyberattack exposes connected device security risks

Device Authority warns that a cyberattack affecting around 700 French supermarkets exposes security weaknesses in connected industrial equipment and...

Breast cancer research highlights importance of patient intelligence in pharma

Talking Medicines highlights how AI-powered patient intelligence can help pharmaceutical companies understand breast cancer treatment experiences and identify unmet...

GLP-1 drugs linked to emerging research into mental health and addiction

Research into GLP-1 medicines is expanding beyond weight loss, with studies examining potential links to depression, cognitive function, alcohol...

Talking Medicines examines emerging links between GLP-1 drugs and mental health

Researchers are investigating the potential links between GLP-1 medicines and mental health, with early findings prompting further studies into...

Search